Selected mucolytic, anti-inflammatory and cardiovascular drugs change the ability of neutrophils to form extracellular traps (NETs) by Zawrotniak, Marcin et al.
Regular paper
Selected mucolytic, anti-inflammatory and cardiovascular drugs 
change the ability of neutrophils to form extracellular traps 
(NETs)*
Marcin Zawrotniak, Andrzej Kozik and Maria Rapala-Kozik*
Department of Analytical Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University in Kraków, Kraków, Poland
Neutrophils form the first line of host defense against in-
fections that combat pathogens using two major mech-
anisms, the phagocytosis or the release of neutrophil 
extracellular traps (NETs). The netosis (NET formation) 
exerts additional, unfavorable effects on the fitness of 
host cells and is also involved at the sites of lung infec-
tion, increasing the mucus viscosity and in the circula-
tory system where it can influence the intravascular clot 
formation. Although molecular mechanisms underlying 
the netosis are still incompletely understood, a role of 
NADPH oxidase that activates the production of reac-
tive oxygen species (ROS) during the initiation of NETs 
has been well documented. Since several commonly 
used drugs can affects the netosis, our current study 
was aimed to determine the effects of selected muco-
lytic, anti-inflammatory and cardiovascular drugs on NET 
formation, with a special emphasis on ROS production 
and NADPH oxidase activity. The treatment of neutro-
phils with N-acetylcysteine, ketoprofen and ethamsylate 
reduced the production of ROS by these cells in a dose-
dependent manner. NET formation was also modulated 
by selected drugs. N-acetylcysteine inhibited the netosis 
but in the presence of H2O2 this neutrophil ability was 
restored, indicating that N-acetylcysteine may influence 
the NET formation by modulating ROS productivity. The 
administration of ethamsylate led to a significant reduc-
tion in NET formation and this effect was not restored by 
H2O2 or S. aureus, suggesting the unexpected additional 
side effects of this drug. Ketoprofen seemed to promote 
ROS-independent NET release, simultaneously inhibit-
ing ROS production. The results, obtained in this study 
strongly suggest that the therapeutic strategies applied 
in many neutrophil-mediated diseases should take into 
account the NET-associated effects.
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INTRODUCTION
Neutrophils are the immune cells of primary impor-
tance for the host defense system. During the infections, 
neutrophils leave the blood vessels and are recruited to 
the site of inflammation, where they kill pathogens using 
several mechanisms such as the phagocytosis, degranu-
lation or releasing neutrophil extracellular traps (NETs), 
the latter process also known as netosis (Kumar & Shar-
ma, 2010). NETs seem to be specially designed to catch 
and kill pathogens outside the cell. They are composed 
of decondensed chromatin, decorated with many antimi-
crobial factors released from internal neutrophil granules. 
Nuclear DNA fibers form a trap scaffold responsible for 
keeping all antimicrobial factors at the place of infection 
and providing their high local concentration. Moreover, 
though trapping microbial cells, these prevent the further 
spreading of microorganisms over the host organism 
(Brinkmann et al., 2004). Antimicrobial activity of NETs 
is determined by a number of antibacterial factors, origi-
nally stored in neutrophil granules. Many of these factors 
are proteins with antimicrobial activity such as elastase, 
cathepsin G, proteinase 3, lactoferrin and myeloperoxi-
dase (MPO) as well as short antimicrobial peptides, e.g., 
LL-37 cathelicidin (Urban et al., 2009). All of them can 
inactivate and kill pathogens by neutralizing their viru-
lence factors or disintegrating the pathogen cell mem-
brane (Brinkmann & Zychlinsky, 2012).
A large number of stimuli activate neutrophils to 
release NETs. The netosis can be triggered by chemi-
cal factors such as phorbol-12-myristate-13-acetate 
(PMA), lipopolysaccharide (LPS) and hydrogen per-
oxide as well as by microorganisms, e.g., Escherichia 
coli, Klebsiella pneumoniae, Staphylococcus aureus, Candida 
albicans (Guimarães-Costa et al., 2012). The mechanism 
of NETs release is incompletely understood, but it 
has been well established that at least two different 
ways of NET formation are possible, either depend-
ent or independent on the reactive oxygen species 
(ROS) production (Nishinaka et al., 2011; Kaplan & 
Radic, 2012). The type of netosis is determined by the 
activating factors, especially the type of the encoun-
tered microorganisms. In the ROS-dependent path-
way, a key step is the activation of NADPH oxidase 
(PHOX) that responds with a massive production of 
ROS (Parker et al., 2012). Neutrophils isolated from 
patients with chronic granulomatous disease (CGD), 
in which mutations in PHOX subunits suppress the 
enzyme activity and, hence, the ROS production can-
not release NETs. However, after treatment of the 
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neutrophils with H2O2 the ability of NET production 
is restored. A similar effect, the netosis blocking was 
also observed after treatment of PHOX with diphe-
nyleneiodonium chloride (DPI), the effective enzyme 
inhibitor (Li & Trush, 1998; Nishinaka et al., 2011; 
Bianchi et al., 2009). On the contrary, in the ROS-in-
dependent netosis, NETs are released without PHOX 
activation (Douda et al., 2015). This mechanism, sig-
nificantly faster than the former, was first identified in 
neutrophils that responded to the infections caused by 
Staphylococcus aureus (Pilsczek et al., 2010) and is prob-
ably mediated by mitochondrial ROS and calcium-
activated small conductance potassium ion channels 
(Douda et al., 2015). This pathogen developed several 
defense mechanisms against neutrophils such as es-
caping from phagosomes, the inhibition of phagocyto-
sis and neutralizing ROS (Pilsczek et al., 2010). There-
fore, the external mechanism of pathogen killing, such 
as the NET release should focus particular attention.
Besides antimicrobial activity of NETs, beneficial for 
the host, these structures are also involved in some im-
munological diseases and other pathological processes. 
High NET levels were detected during chronic inflam-
matory, autoimmune disease (SLE), thrombosis, acute 
lung injury, cystic fibrosis and other (Amulic et al., 2012; 
Zawrotniak & Rapala-Kozik, 2013). In most cases the 
presence of NETs have a negative impact on the fit-
ness of host tissues, because the high concentration of 
antimicrobial agents and ineffective clearance of NETs 
led to a number of tissue damages at the site of NET 
production (Saffarzadeh et al., 2012). But in some situa-
tions NETs supports the host functions, e.g., in a bleed-
ing, where NETs can serve as a scaffold for clot forma-
tion and help trapping the blood morphotic elements or 
proteins, like platelets or fibrinogen (Fuchs et al., 2010; 
Fuchs et al., 2012).
However, the release of NETs or ROS production 
by neutrophils can be modified by specific inhibitors or 
drugs. DPI prevents netosis on ROS-dependent path-
way, DNase helps in NET clearance by degradation of 
their scaffold (Duranton et al., 2000; Papayannopoulos et 
al., 2011), acetylsalicylic acid can inhibit the MPO activ-
ity (Lapponi et al., 2013), cyclosporine A modulate cal-
cium flux and inhibit the ROS-independent pathway of 
netosis (Gupta et al., 2014). Most of these compounds 
directly target the neutrophil activity, preventing negative 
impact of NET release. But commonly used drugs like 
statins (Chow et al., 2010), flavonoids and aminosalicylic 
acid (Kirchner et al., 2013) sometimes show an undesir-
able effects against neutrophils, switching off some help-
ful mechanisms of these immune cells (Lapponi et al., 
2013).
Application of proteomics to the identification of 
NET components or microbial proteins involved in 
pathogen trapping by NETs suggests that a combination 
of proteomic approach and traditional biochemical meth-
ods can provide new insights into the role of neutrophils 
in immune responses. Moreover, extension of those 
studies on disease-related networks can improve under-
standing of inflammatory diseases or identify biomark-
ers of those diseases, and reveal new therapeutic targets 
(McLeish et al., 2013).
Our current study was aimed to reveal the impact of 
selected drugs on ability of neutrophils to release NETs, 
with a special focus on ROS production and PHOX ac-
tivity. We examined selected mucolytic (N-acetylcysteine), 
anti-inflammatory (clemastine, ketoprofen, hydrocorti-
sone) and cardiovascular (ethamsylate) drugs, commonly 
used in therapy of various diseases.
MATERIAL AND METHODS
Clemastine was purchased from Polfa (Warszawa, Po-
land); Ethamsylate was from Galena (Wrocław, Poland); 
Hydrocortisone was from Jelfa (Jelenia Góra, Poland); 
Ketoprofen was from Lek S.A. (Stryków, Poland); Lu-
minol, N-acetylcysteine, Polyvinyl alcohol, Tetrazolium 
dye (MTT) were from Sigma-Aldrich (Saint Louis, USA); 
Micrococcal nuclease was from Roche (Penzberg, Ger-
many); Pancoll 1.077 g/l was from PAN-Biotech (Aid-
enbach, Germany); Sytox Green was from Molecular 
Probes (Eugene, USA).
Isolation of neutrophils from human peripheral 
blood. Human neutrophils were isolated from EDTA-
treated whole blood obtained from healthy donors, sup-
plied by the Regional Blood Donation Center, Kraków, 
Poland. The neutrophil-containing fraction was collected 
by Pancoll 1.077 g/l gradient separation, performed ac-
cording to the manufacturer’s protocols. The high-densi-
ty fraction, containing neutrophils and erythrocytes, were 
mixed with a solution of polyvinyl alcohol (1%) and 
incubated for 20 min at room temperature. The upper 
layer was collected and centrifuged. The cell pellet was 
transferred to hypotonic solution to remove erythrocytes 
contamination by their lysis. After washing with phos-
phate buffered saline (PBS) the cells were resuspended 
in RPMI 1640 medium (phenol-red free). The neutrophil 
purity was typically >95%, as assessed by forward-scatter 
and side-scatter flow cytometric analyses.
Neutrophil viability assay. Neutrophils (2 × 105 
cells/well) were suspended in RPMI medium in the 
wells of a 96-well microplate, treated with various con-
centrations of selected drugs for 30 minutes and washed 
3 times with PBS. Then, the cells were incubated with 
MTT solution (0.5 mg/ml) for 2 hours. The purple pre-
cipitate was solubilized with dimethylsulfoxide (DMSO) 
and absorbance at 560 nm was measured using a BioTek 
Synergy H1 microplate reader (BioTek, Winooski, USA).
Neutrophils (2.2 × 105 cells per well), pre-treated 
for 30 minutes with various concentrations of selected 
drugs and washed 3 times with PBS, were allowed to 
settle in the wells of 96-well white microplate, at 37°C 
for 30 min, in 160 µl of Krebs-Ringer phosphate buffer 
containing freshly prepared luminol solution (10–6 M). As 
a control, the untreated cells were used. The neutrophils 
were then stimulated with 20 µl of 25 nM PMA or PBS 
(as a negative control). The chemiluminescence was re-
corded immediately after PMA application for one hour, 
using a BioTek Synergy H1 microplate reader, with one-
second integration time.
NET visualization and quantification. The 12-well 
microplates (Greiner Bio-One, Germany) were coated 
with 0.01% poly-L-lysine in RPMI at 4°C overnight. 
After drying, 1.5 × 106 neutrophils suspended in 900 μl 
RPMI were seeded into each well. The cells were in-
cubated for 30 minutes at 37°C, and then the attached 
neutrophils were treated with specified concentrations 
of each tested drugs for 30 minutes. After washing with 
PBS, the cells were stimulated at 37°C for 3 hours with 
various factors: 25 nM PMA, 5 μM DPI, 0.03% H2O2 or 
S. aureus at a multiplicity of infection (MOI) of 10.
Visualisation. After incubation, Sytox Green dye was 
added to each well at the final concentration of 1 μM. 
NETs were observed in a fluorescence microscope 
Nikon Eclipse Ti (Nikon Instruments, Melville, USA).
Quantification. After incubation, the wells were 
washed 3 times with PBS, then 400 μl of micrococ-
cal nuclease (1 U/ml) were added and the microplates 
were incubated at 37°C for further 20 minutes. The 
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enzymatic reaction was stopped with EDTA (100 μg/
ml), the solution was collected and Sytox Green at the 
final concentration 1 μM was added. Portions (50 μl) 
of each sample were transferred to 96-well microplates 
and fluorescence was measured using the Biotek Syn-
ergy H1 microplate reader at excitation 465 nm and 
emission 525 nm.
RESULTS
All drugs tested in this study do not lead to death of 
neutrophils in vitro
Bearing in mind that NETs can influence mucolytic 
properties of lung tissues, cardiovascular conditions and 
inflammatory responses, for this study we chose five 
medicaments, commonly used both in health emergency 
conditions or in long-term therapy, i.e., clemastine, hy-
drocortisone, N-acetylcysteine, ketoprofen and etham-
sylate.
The concentrations of the tested drugs were used in 
accordance with their expected concentrations in a hu-
man serum after administration of typical therapeutic 
doses by injection directly to circulatory system or ad-
ministered orally to adult patients. Most of these values 
are specified in literature (Regenthal et al., 1999; Borg-
ström et al., 1986; Hernandez et al., 2004), but if not, the 
concentrations were calculated as the ratio of the thera-
peutic dose administered to the average volume (6 liters) 
of blood in the human body.
To exclude any toxic effects of selected drugs on neu-
trophils, we checked the viability of the cells after treat-
ment by selected compounds for 30 minutes, in a wide 
range of drug concentrations. As a negative control the 
untreated cells were used, and for a positive control the 
cells were treated with 25 nM PMA.
The viability was tested using MTT test, in which the 
reduction of tetrazolium dye to purple formazan was 
monitored at 560 nm. Viable cells performed the reac-
tion efficiently and the yield of the reaction indicated the 
state of viability, while a decrease in the amount of the 
product suggested cell death. None of tested drugs led 
to neutrophil death under tested conditions (Fig. 1). Ex-
cept for ethamsylate, the p-value for the comparison of 
the samples versus the negative control > 0.1, suggesting 
that the differences were insignificant. The p-value for 
ethamsylate was *p< 0.05, but the absorbance level for 
the drug was higher than for negative control, suggesting 
the effect of prolonged lifetime of neutrophils. Positive 
control showed highly increased cell death, which is as-
sociated with the activation of netosis pathway.
ROS production by PMA stimulated neutrophils 
is inhibited by N-acetylcysteine, ketoprofen and 
ethamsylate
Neutrophils produce high amounts of ROS, serving as 
antimicrobial factors or signaling molecules. The mecha-
nism of ROS production that depends on the activity 
of PHOX is highly efficient and very fast. The activity 
of this enzyme can be modified by many compounds, 
causing dramatic changes in physiology and immune re-
sponse of neutrophils. A chemical agent, PMA, potently 
activates neutrophils leading to production of ROS in 
few minutes, and in consequence to NET release.
We checked the effect of neutrophil pretreatment with 
tested drugs on the ability of the cells to produce ROS 
in a response to further PMA stimulation. All drugs 
were tested at a broad range of concentrations, cover-
ing their concentrations in serum after administration of 
therapeutic dosages.
The obtained results are presented as the percentage 
ratio of maximal luminescence signal from drug-treat-
ed cells to untreated cells, stimulated by PMA (Fig. 2). 
Luminescence of negative control (cells not treated by 
any chemicals) showed a very low level of spontaneous 
ROS release by neutrophils. The samples pretreated with 
PHOX inhibitor (DPI) presented only 10% of total ROS 
production by neutrophils with active PHOX.
N-acetylcysteine (NAC), ketoprofen and ethamsylate 
caused a significant and dose-dependent inhibition of 
ROS generation. At the concentrations that correspond 
to the therapeutic doses, NAC, ketoprofen and etham-
sylate decreased the ROS production by about 30% 
(Fig. 2A–C). Higher concentrations of these drugs led to 
a further reduction of ROS amount to the level that cor-
responded to DPI action.
On the contrary, clemastine and hydrocortisone exert-
ed slight effects on ROS generation by neutrophils under 
PMA treatment, suggesting no influence on PHOX ac-
tivity in vitro. Only at the highest concentration of clem-
astine a rapid decrease of ROS release was observed, but 
it was probably caused by overdose and cell death.
Release of NETs is modulated by N-acetylcysteine, 
ketoprofen and ethamsylate
Because the release of NETs by neutrophils de-
pends on various factors, such as stimulant nature, 
cell fitness and the type of netosis-activation pathway, 
we checked the influence of pretreatment of neutro-
phils with tested drugs on the subsequent netosis pro-
cess. Given results presented (Fig. 3A), some of tested 
drugs modified the neutrophils response as the NET 
release. Neutrophils pretreated with 0.03 μM clem-
Figure 1. The viability of neutrophils in the presence of tested 
drugs, determined by MTT assay.
Neutrophils (2x105 cells/well) were suspended in RPMI medium 
and treated with selected concentrations of NAC, ketoprofen, 
ethamsylate, clemastine and hydrocortisone for 30 minutes. Then, 
neutrophils were incubated with solution of MTT dye (0.5 mg/ml) 
for 2 hours and the absorbance at 560 nm was measured. Data 
represent mean values of absorbance from two replicates ± S.D. 
Asterisks denote differences considered as statistically significant 
at p<0.05 as compared to the negative control (untreated cells) by 
one-way ANOVA with Dunnett’s multiple comparison test.
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astine and 0.7 μM hydrocortisone, followed by the 
stimulation with PMA, produced NETs at the same 
level as the positive control, without any differences 
in amount, shapes and surface area of released DNA. 
Moreover, the results were confirmed by the quanti-
fication of extracellular DNA released by neutrophils 
pretreated with the drugs at the wide concentration 
range (Fig. 3B). It suggests that these two drug types 
have no impact on netosis process regardless of its 
mechanism, whether ROS-dependent or ROS-inde-
pendent. On the other hand, 10 μM NAC and 48 μM 
ethamsylate (Fig. 3A) caused a high decrease in NET 
production by neutrophils. After a half-hour treat-
ment with therapeutic doses of drugs, the number of 
neutrophils that released traps was significantly lower 
than in the positive control, but still higher than in 
the negative control. However, on Fig. 3B the dose-
dependent inhibition of NETs release by neutrophils 
was observed. The fluorescence intensity detected 
with 100 μM NAC dropped to 30% of positive con-
trol. Similarly, with 480 μM ethamsylate only 40% of 
fluorescence was measured (Fig. 3B).
A quite different effect was observed for neutro-
phils treated with 20 μM ketoprofen. In contrast to 
results described above, ketoprofen did not cause 
any inhibition of netosis, but instead significantly in-
creased release of the NETs, in comparison to posi-
tive control (Fig. 3A). The results were confirmed by 
dose-dependent correlation (Fig. 3B); for 20 μM and 
200 μM ketoprofen the amount of released NETs in-
creased up to 140% and 160% of the positive control, 
respectively.
Figure 2. Luminescence assay of ROS production by neutrophils treated with tested drugs.
Neutrophils (2 x 105 cells/well) were suspended in RPMI medium and treated with selected concentrations of NAC (A), ketoprofen (B), 
ethamsylate (C), clemastine (D) and hydrocortisone (E) or 10 μM DPI for 30 minutes. After washing and re-suspension in a luminol solu-
tion, the cells were stimulated with 25 nM PMA and thereafter the luminescence was measured for 1 h. The arrows point out the ex-
pected concentration of the drugs in the serum. Data presented the values of maximum luminescence ± S.D. from two replicates as the 
percentage ratio of maximum luminescence of drug-treated neutrophils to untreated cells. Asterisks denote differences considered as 
statistically significant at P < 0.05 (A, B, C). No significant differences were marked as “ns”.
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Figure 3. Effect of selected drugs on the ability of neutrophils to release NETs.
Isolated neutrophils, transferred into 12-wells microplate (1.5 x 106
 
cells/well) were treated with specified concentrations of each tested 
drugs for 30 minutes. After washing, the neutrophils were stimulated for 3 hours with 25 nM PMA. For negative and positive control the 
cells were not treated with any drugs; for the negative control the cells were also not stimulated with PMA. (A) Extracellular DNA was 
stained with Sytox Green and visualized in fluorescence microscope. (B) Partially digested DNA was collected from each well after mic-
rococcal nuclease treatment and quantified at presence of Sytox Green by fluorescence measurement. Data presented the values ± S.D. 
from two replicates as the percentage ratio versus positive control. Differences were considered statistically significant at P < 0.05 as com-
pared to the positive control by one-way ANOVA with Dunnett’s multiple comparison test. At the figures, significant differences were 
marked with asterisks (*P < 0.05, **P < 0.01, ***P < 0.001).
A
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The mechanisms of N-acetylcysteine, ethamsylate and 
ketoprofen influence on NET formation by neutrophils 
are different
Taking into account the observed effects of selected 
drugs on the ability of neutrophils to release NETs, we 
further examined in details this process, considering two 
different, ROS-dependent and ROS-independent path-
ways. We focused on three of examined drugs — NAC, 
ethamsylate and ketoprofen — because only those me-
dicaments showed a significant effect on neutrophils. 
The neutrophils were treated with a therapeutic concen-
tration of each drug as previously but their further stim-
ulation toward NET release was performed using differ-
ent stimulants. PMA is able to trigger ROS-dependent 
NET formation through the protein kinase C (PKC)-
dependent signaling pathway (Keshari et al., 2012). DPI, 
the inhibitor of PHOX, switches off the ROS-dependent 
netosis pathway by blocking ROS production. Hydrogen 
peroxide allows to produce NETs by neutrophils, by-
passing NADPH-oxidase activity (Nishinaka et al., 2011).
The ROS-independent netosis pathway is triggered by 
activation of neutrophils upon the contact with S. aureus 
(Pilsczek et al., 2010). Application of the stimulants dur-
ing neutrophils treatment with above selected drugs can 
help in identification of the mechanisms, which were af-
fected in neutrophils by these medicaments. As present-
ed on Fig. 4A, the treatment of neutrophils with N-ace-
tylcysteine influenced the NET production on the ROS-
dependent process, mediated by PHOX. The amount of 
DNA released to extracellular space in response to PMA 
treatment was more than four times lower for neutro-
phils treated with NAC as compared to untreated cells. 
After inhibition of PHOX with DPI, the amount of 
NETs for treated and for control samples dropped to 
the level of the negative control. The NET release dur-
ing cell treatment with 0.03% H2O2 was not influenced 
by NAC. This drug also exerted no effect on ROS-inde-
pendent netosis pathway, because cells treated and un-
treated with NAC released the same level of DNA in 
response to the contact with S. aureus cells. In this case, 
DPI had no effect on neutrophil ability to form NETs.
The effect of ethamsylate on netosis pathway seemed 
to be more complex. A significant inhibition of NET 
formation by neutrophils treated with ethamsylate was 
observed as regards the ROS-dependent netosis path-
way, after stimulation with PMA (Fig. 4B). The amount 
of released NETs was three times lower in cells under 
drug presence than in control cells. DPI blocked this 
part of NET formation. Stimulation of neutrophils with 
0.03% H2O2 have no effect on restoration of the ability 
of drug-treated neutrophils to release NETs. The par-
tial effect was observed as regards the ROS-independent 
pathway. Stimulation of neutrophils with S. aureus gave 
three times lower amount of released DNA. It is pos-
sible that ethamsylate can act on the common part of 
ROS-dependent and ROS-independent netosis pathways, 
causing a significant decrease in NET formation.
The action of ketoprofen is quite different and mul-
tifaceted. Although ketoprofen presented the ability to 
inhibit ROS production by PHOX (Fig. 2B), the drug 
was also involved in an additional effect of NET gen-
eration, probably on the ROS-independent pathway (Fig. 
4C). In all treatments, neutrophils preincubated with ke-
toprofen exhibited increased production of NETs. More-
over, unstimulated neutrophils, treated with 20 μM keto-
profen released two-fold more NETs than control cells. 
An activation of ROS-dependent pathway by PMA led 
to release of NETs by both types of cells at the same 
level. DPI treatment pointed additional stimulation of 
NETs release by ketoprofen treatment. There was also 
no significant difference in the amount of DNA released 
by neutrophils stimulated with hydrogen peroxide. In a 
ROS-independent pathway ketoprofen-treated neutro-
phils produce two-fold more NETs than untreated cells 
stimulated with S. aureus. We can speculate that ketopro-
fen is able to activate NET production involving differ-
ent netosis pathways.
DISCUSSION
Neutrophils play an important role in keeping homeo-
stasis of human body and preventing spreading microbial 
Figure 4. NET release by neutrophils in response to NAC, etham-
sylate and ketoprofen.
Neutrophils (1.5 x 106 cells/well) were treated with specified con-
centrations of the drugs for 30 minutes. After washing, the neu-
trophils were stimulated for 3 hours with different stimulants: 25 
nM PMA, 0.03% H2O2 or S. aureus (MOI 10). Control cells (open 
bars) were not treated with drugs. A 5 μM DPI was used to exam-
ine the ROS-independent netosis pathway. Partially digested DNA 
was collected from each well after micrococcal nuclease treatment 
and quantified as it was presented above.
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infections in the host. These tasks are executed using 
various mechanisms, one of the major being the release 
of NETs. The netosis is also important for many other 
physiological and pathological processes in the human 
organism (Zawrotniak & Rapala-Kozik, 2013). This spe-
cial activity of neutrophils can be modulated at different 
stages by various types of drugs or other chemical fac-
tors (Lapponi et al., 2013).
In the current study we examined the effects of a 
range of medicaments that can affect the netosis pro-
cesses, proceeding through both oxidative and non-oxi-
dative pathways. We selected five drugs commonly used 
in health emergency conditions or in long-term therapy.
This study helped to understand possible consequenc-
es of the patient treatment with examined drugs, as well 
as presented the different aspects of the drug usage, not 
taken into account so far.
One of the broadly used drugs is NAC. This thiol 
mucolytic drug exerts many different therapeutic effects 
on the human body. The main application concerns a 
support therapy in almost all respiratory diseases, such 
as acute respiratory distress syndrome, acute lung inju-
ry, cystic fibrosis etc. NAC was also proposed as use-
ful drug in therapy of cancer and cardiovascular diseases. 
(Masha & Martina, 2014; Wu et al., 2014; Zafarullah et 
al., 2003; Kharazmi et al., 1988; Holdiness, 1991). The 
current examination of ROS production by neutrophils 
treated with NAC showed that this drug decreased 
ROS amounts in a dose-dependent manner. This activ-
ity could be associated with NAC ability to scavenge 
free radicals, which was earlier presented for higher 
concentration of the used drug (Zafarullah et al., 2003; 
Kharazmi et al., 1988; Drost et al., 1991; Kirchner et al., 
2013). Our results also suggested that NAC probably 
had to be transported into the neutrophil cell because 
its effect was observed after extensive cell washing. Ad-
ditionally, neutrophils can exert long-term effects even 
after short time of incubation with NAC (Sadowska et 
al., 2006; Stolarek et al., 2002), a report that confirms our 
observation. As a further consequence, NAC can inhibit 
the activity of PHOX or other neutrophil enzymes such 
as MPO (Zafarullah et al., 2003; Kharazmi et al., 1988; 
Drost et al., 1991), leading to a significant decrease in 
DNA release into extracellular space. Such the effect was 
also presented by Kirchner et al. (2013) but at a slightly 
higher dose of the drug than its expected concentration 
in serum. Our detailed examination of NAC effects on 
the ability of neutrophils to release NETs showed that 
this drug acted directly on the ROS-dependent netosis 
pathway, as neutrophils pretreated with therapeutic con-
centration of NAC did not release NETs in response 
to PMA treatment, in contrast to the stimulation with 
0.03% H2O2. Moreover, ROS-independent netosis path-
way was not susceptible to the drug action. Referring to 
the main applications of NAC as a pulmonary drug, the 
described results suggest an important role of NAC in 
respiratory disease treatment. NET release can serve as 
an efficient antimicrobial weapon of the host, but had 
also negative consequences, such as increasing viscosity 
of mucus, e.g., in cystic fibrosis, or the intensification of 
alveoli damages by NET-bound proteolytic enzymes or 
released ROS. However, neutrophils often release NETs 
in lungs as a sterile inflammation, and in this case the 
local application of NAC seems to be a very interesting 
proposal for acute and chronic lung disease treatment, 
where inhibition of NET production may protect the al-
veoli walls from damages.
Ethamsylate belongs to the cardiovascular drugs, com-
monly used in a massive hemorrhage, bleeding, pro-
longed menstruation or vascular purpura (El-Shabrawy 
et al., 2004). This non-thrombogenic hemostatic agent 
acts on the vascular wall, restoring capillary resistance. 
However, the mechanism of its action is still poor un-
derstood. It is known that ethamsylate exerts an effect 
on platelet aggregation (Alvarez-Guerra et al., 2002; 
Hernandez et al., 2004). On the other hand, activated 
platelets induce the formation of NETs in transfusion-
related acute lung injury (Caudrillier et al., 2012). There 
are no reports about the impact of ethamsylate on the 
activity and function of neutrophils, although the drug is 
known to activate lymphocytes and inhibit macrophages 
(Dayrens et al., 1983). Our study presented for the first 
time that neutrophil treatment with ethamsylate caused 
a significant, dose-dependent decrease of ROS produc-
tion. Even a short incubation of neutrophils in pres-
ence of this drug was sufficient to reduce the amount of 
ROS. Sack and Ceruttil (1973) showed that ethamsylate 
bounds to the cell surface and changes the net mem-
brane surface charge, a finding that could explain the 
rapid response of neutrophils to ethamsylate action.
The reduction of NET formation by neutrophils, 
treated with ethamsylate seems to be clear as regards the 
ROS inhibition. However, the precise examination of 
possible influence of the drug on neutrophils presented 
that the ROS-independent pathway was also the target 
for ethamsylate, or that the drug can influence the com-
mon part of both netosis pathways. To explain the exact 
action of this drug, further studies are needed.
However, treatment of bleeding with ethamsylate can 
decrease efficiency of clot formation in blood vessels, 
resulting from inhibited netosis. Moreover, ethamsylate 
seems to act as a double-edged sword, on one hand 
increasing a tightness of the blood vessels but, on the 
other, limiting the possibility of clot formation. Applica-
tion of this drug may be interesting as a support therapy 
in vein thrombosis or myocardial infarction, where the 
restriction of ability to clot formation is needed.
Ketoprofen is a non-steroidal, anti-inflammatory drug 
(NSAID) commonly used for treatment of pain, fe-
ver and inflammation (Costa et al., 2006). However, the 
impact of ketoprofen or other NSAIDs on netosis has 
never been examined. At low doses, ketoprofen inhibits 
the synthesis of prostaglandins, but for anti-inflammato-
ry action higher doses are required (Costa et al., 2006), 
at which the drug inhibits the oxidative burst of neutro-
phils. As the effectiveness of low-dose treatment with 
ketoprofen was still under discussion (Benbarek et al., 
2012; Costa et al., 2006) we performed the analysis of 
its influence on ROS production at the a wide range of 
drug concentration and clearly observed lowering ROS 
production by ketoprofen-pretreated neutrophils at the 
whole concentration range tested. Surprisingly, at the 
same time the NET production increased significantly. 
A detailed examination of the influence of ketoprofen 
treatment on netosis pointed out on the activation of 
ROS-independent pathway, reaffirming the anti-inflam-
matory properties of this drug. However, the details of 
the mechanism of its action are still not clear and need 
more extended studies.
Clemastine, that modulates the activation and chem-
otaxis of immune cells (Cíž & Lojek, 2013), did not 
presented any significant influence on either ROS pro-
duction or NET generation at therapeutic doses. Some 
impact on PMA-activated ROS production was detected 
only at clemastine concentration that 3-fold exceeds the 
medically applied dose.
The effect of hydrocortisone on neutrophils has been 
repeatedly studied, and showed the inhibition of phago-
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cytosis (Petroni et al., 1988) and degranulation (Coates et 
al., 1983), as well as impaired chemotaxis (Ward, 1966). 
Moreover, it was presented that hydrocortisone, at high 
dosage, efficiently inhibited the oxidative burst of neu-
trophils in vivo and in vitro (Dandona et al., 2001, 1999, 
1998). However, our results, in which the medically ap-
plicable doses were used, did not present any effects of 
hydrocortisone on oxidative or not-oxidative pathways 
of NET formation.
All presented results are summarized in Table 1 and 
can be helpful in the consideration of the medical ap-
plication of analyzed drugs where the possible impact on 
netosis processes may influence the progression of the 
disease or its treatment.
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